Palvella Secures U.S. Patent for QTORIN™ Pitavastatin, Extending Protection to 2043
PVLA has more than doubled off its 52-week low of $20.2.
Summary
Palvella Therapeutics announced the issuance of a new U.S. patent for its QTORIN™ pitavastatin program, exclusively licensed from Yale University, providing intellectual property protection until 2043. This patent strengthens the IP position for a key pipeline asset targeting porokeratosis, including disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease affecting over 50,000 U.S. patients with no FDA-approved therapies. Securing long-term IP significantly de-risks the asset and enhances its commercial potential as a potential first-in-disease therapy. The company plans to initiate a Phase 2 clinical trial for QTORIN™ pitavastatin in DSAP in the second half of 2026.
At the time of this announcement, PVLA was trading at $117.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $20.20 to $151.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.